
The United States of America



Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Joseph Matat

Performing the Functions and Duties of the
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office



US009708372B2

(12) United States Patent

Bimmler et al.

(54) AGONISTIC AUTOANTIBODIES TO THE ALPHA1-ADRENERGIC RECEPTOR AND THE BETA2-ADRENERGIC RECEPTOR IN ALZHEIMER'S AND VASCULAR DEMENTIA

(71) Applicants: E.R.D.E.-AAK-DIAGNOSTIK
GMBH, Berlin (DE);
MAX-DEL-BRUCK-CENTRUM FÜR
MOLEKULARE MEDIZIN, Berlin
(DE)

(72) Inventors: Marion Bimmler, Königs
Wusterhausen Ot Zernsdorf (DE); Peter
Karczewski, Berlin (DE); Petra
Hempel, Berlin (DE)

(73) Assignees: E.R.D.E.-AAK-DIAGNOSTIK
GMBH, Berlin (DE);
MAX-DEL-BRUCK-CENTRUM FÜR
MOLEKULARE MEDIZIN, Berlin
(DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 58 days.

(21) Appl. No.: 14/749,408

(22) Filed: Jun. 24, 2015

(65) Prior Publication Data

US 2015/0291661 A1 Oct. 15, 2015

Related U.S. Application Data

(62) Division of application No. 14/238,450, filed as application No. PCT/EP2012/063789 on Jul. 13, 2012, now abandoned.

(30) Foreign Application Priority Data

Aug. 12, 2011 (EP) 11177414

(51) Int. Cl.

C07K 7/08 (2006.01)

C07K 16/18 (2006.01)

G01N 33/566 (2006.01)

C07K 14/705 (2006.01)

A61M 1/36 (2006.01)

G01N 33/564 (2006.01)

 (10) Patent No.: US 9,708,372 B2

(45) **Date of Patent: Jul. 18, 2017**

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

2009/0181380 A1 7/2009 Belouchi et al. 2011/0166844 A1 7/2011 Gustafsson et al.

FOREIGN PATENT DOCUMENTS

WO	WO 02/09374 A2	1/2002
WO	WO 02/16431 A2	2/2002
WO	WO 2005/109000 A2	11/2005
WO	WO 2006/113602 A2	10/2006
WO	WO 2009/090227 A2	7/2009

OTHER PUBLICATIONS

Google 2016 "definition of indicate" accessed from google.com on Oct. 14, 2016.*

Kunze 2010 "agonistic autoantibodies against the alpha.1-adrenoceptor in patients with morbus alzheimer and vascular dementia" poster presentation abstract.*

Hwa et al. 1995 "Identification of critical determinants of α_1 -adrenergic receptor subtype selective agonist binding" *J Biol Chem* 270(39): 231189-23195.

Kunze, R. 2010 "Agonistic autoantibodies against the alphaladrenoceptor in patients with Morbus Alzheimer and vascular dementia" *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* 6:4, S413 (Poster Abstract).

Lei et al. 2005 "Novel human alphala adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function" *Naunyn Schmiedebergs Arch Pharmacol* 371 (3): 229-239

Ni, Y. et al. 2006 "Activation of β_2 -adrenergic receptor stimulates γ -secretase activity and accelerates amyloid plaque formation" *Nature Medicine* 12: 1390-1396.

Karczewski, P. et al. 2012 "Agonistic autoantibodies to the α_1 -Adrenergic Receptor and the β_2 -adrenergic receptor in Alzheimer's and vascular Dementia" *Scandinavian Journal of Immunology* 75: 524-530.

* cited by examiner

Primary Examiner — Adam M Weidner (74) Attorney, Agent, or Firm — Knobbe, Martens, Olson & Bear, LLP

(57) ABSTRACT

The invention relates to means for detecting, binding, removing and/or neutralizing agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia.

15 Claims, 4 Drawing Sheets